Fmr LLC Acquires 89,601 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)

Fmr LLC increased its stake in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 26.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 431,906 shares of the biotechnology company’s stock after purchasing an additional 89,601 shares during the quarter. Fmr LLC’s holdings in Heron Therapeutics were worth $859,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in HRTX. nVerses Capital LLC acquired a new position in shares of Heron Therapeutics in the second quarter valued at approximately $27,000. HB Wealth Management LLC bought a new stake in Heron Therapeutics during the 2nd quarter worth approximately $35,000. Cutter & CO Brokerage Inc. bought a new stake in Heron Therapeutics during the 3rd quarter worth approximately $39,000. B. Riley Wealth Advisors Inc. acquired a new position in Heron Therapeutics in the 2nd quarter valued at approximately $41,000. Finally, Sei Investments Co. bought a new position in shares of Heron Therapeutics during the second quarter valued at $44,000. Institutional investors own 80.01% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on HRTX. StockNews.com raised shares of Heron Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, December 11th. Needham & Company LLC reaffirmed a “buy” rating and set a $4.00 target price on shares of Heron Therapeutics in a report on Wednesday, December 4th.

Heron Therapeutics Stock Performance

Heron Therapeutics stock opened at $1.65 on Wednesday. The firm has a 50 day moving average price of $1.57 and a two-hundred day moving average price of $2.24. Heron Therapeutics, Inc. has a 52-week low of $1.04 and a 52-week high of $3.93. The firm has a market cap of $250.96 million, a price-to-earnings ratio of -9.17 and a beta of 1.67.

Heron Therapeutics (NASDAQ:HRTX) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.03) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.03). The firm had revenue of $32.81 million for the quarter, compared to the consensus estimate of $36.40 million. During the same period in the prior year, the business earned ($0.17) EPS. As a group, equities research analysts predict that Heron Therapeutics, Inc. will post -0.13 EPS for the current fiscal year.

Heron Therapeutics Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.